JP2025066770A5 - - Google Patents

Info

Publication number
JP2025066770A5
JP2025066770A5 JP2025008195A JP2025008195A JP2025066770A5 JP 2025066770 A5 JP2025066770 A5 JP 2025066770A5 JP 2025008195 A JP2025008195 A JP 2025008195A JP 2025008195 A JP2025008195 A JP 2025008195A JP 2025066770 A5 JP2025066770 A5 JP 2025066770A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025008195A
Other languages
Japanese (ja)
Other versions
JP2025066770A (ja
Filing date
Publication date
Priority claimed from CN202010188038.1A external-priority patent/CN113402612A/zh
Application filed filed Critical
Publication of JP2025066770A publication Critical patent/JP2025066770A/ja
Publication of JP2025066770A5 publication Critical patent/JP2025066770A5/ja
Pending legal-status Critical Current

Links

JP2025008195A 2020-03-17 2025-01-21 Cd19及びcd20を標的とする組み合わされたキメラ抗原受容体並びにその適用 Pending JP2025066770A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN202010188038.1A CN113402612A (zh) 2020-03-17 2020-03-17 靶向cd19和cd20的联合嵌合抗原受体及其应用
CN202010188038.1 2020-03-17
US16/877,069 US11207349B2 (en) 2020-03-17 2020-05-18 Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
US16/877,069 2020-05-18
PCT/CN2020/109645 WO2021184673A1 (en) 2020-03-17 2020-08-17 Combined chimeric antigen receptor targeting cd19 and cd20 and application thereof
JP2022506548A JP7624967B2 (ja) 2020-03-17 2020-08-17 Cd19及びcd20を標的とする組み合わされたキメラ抗原受容体並びにその適用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022506548A Division JP7624967B2 (ja) 2020-03-17 2020-08-17 Cd19及びcd20を標的とする組み合わされたキメラ抗原受容体並びにその適用

Publications (2)

Publication Number Publication Date
JP2025066770A JP2025066770A (ja) 2025-04-23
JP2025066770A5 true JP2025066770A5 (enExample) 2025-10-10

Family

ID=77677447

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2022506548A Active JP7624967B2 (ja) 2020-03-17 2020-08-17 Cd19及びcd20を標的とする組み合わされたキメラ抗原受容体並びにその適用
JP2022506726A Active JP7212222B2 (ja) 2020-03-17 2021-03-17 Cd19及びcd20を標的とする組み合わされたキメラ抗原受容体並びにその適用
JP2022202035A Active JP7624961B2 (ja) 2020-03-17 2022-12-19 Cd19及びcd20を標的とする組み合わされたキメラ抗原受容体並びにその適用
JP2025008195A Pending JP2025066770A (ja) 2020-03-17 2025-01-21 Cd19及びcd20を標的とする組み合わされたキメラ抗原受容体並びにその適用

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2022506548A Active JP7624967B2 (ja) 2020-03-17 2020-08-17 Cd19及びcd20を標的とする組み合わされたキメラ抗原受容体並びにその適用
JP2022506726A Active JP7212222B2 (ja) 2020-03-17 2021-03-17 Cd19及びcd20を標的とする組み合わされたキメラ抗原受容体並びにその適用
JP2022202035A Active JP7624961B2 (ja) 2020-03-17 2022-12-19 Cd19及びcd20を標的とする組み合わされたキメラ抗原受容体並びにその適用

Country Status (30)

Country Link
US (5) US11207349B2 (enExample)
EP (2) EP3989986B1 (enExample)
JP (4) JP7624967B2 (enExample)
KR (2) KR102520550B1 (enExample)
CN (2) CN113402612A (enExample)
AU (2) AU2021238330B2 (enExample)
BR (1) BR112022018677A2 (enExample)
CA (2) CA3169235A1 (enExample)
CL (1) CL2022002522A1 (enExample)
CO (1) CO2022014259A2 (enExample)
CR (1) CR20220507A (enExample)
DK (1) DK3989986T3 (enExample)
DO (1) DOP2022000195A (enExample)
EC (1) ECSP22079948A (enExample)
ES (1) ES3039539T3 (enExample)
FI (1) FI3989986T3 (enExample)
HR (1) HRP20251006T1 (enExample)
IL (2) IL296473B2 (enExample)
LT (1) LT3989986T (enExample)
MX (1) MX2022011554A (enExample)
NZ (1) NZ793365A (enExample)
PE (1) PE20231643A1 (enExample)
PH (1) PH12022552463A1 (enExample)
PL (1) PL3989986T3 (enExample)
PT (1) PT3989986T (enExample)
RS (1) RS67131B1 (enExample)
SI (1) SI3989986T1 (enExample)
SM (1) SMT202500287T1 (enExample)
UA (1) UA129998C2 (enExample)
WO (2) WO2021184673A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技(香港)有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
US12227567B2 (en) 2017-07-25 2025-02-18 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
CN116063520A (zh) 2019-01-30 2023-05-05 真和制药有限公司 抗gal3抗体及其用途
CN118546959A (zh) 2019-03-05 2024-08-27 恩卡尔塔公司 Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
CN113402612A (zh) * 2020-03-17 2021-09-17 西比曼生物科技(香港)有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
KR102739632B1 (ko) * 2022-02-09 2024-12-05 한림대학교 산학협력단 항-cd20 키메릭 항원 수용체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 및 이의 제조 방법
WO2023208157A1 (zh) * 2022-04-29 2023-11-02 上海先博生物科技有限公司 靶向cd19的嵌合抗原受体及其应用
CN114990069B (zh) * 2022-05-17 2023-09-22 郑州大学第一附属医院 一种过表达slc43a2的嵌合抗原受体t细胞的制备方法和应用
EP4577571A1 (en) * 2022-08-26 2025-07-02 Lentigen Technology, Inc. Compositions and methods for treating cancer with fully human anti-cd20/cd19 immunotherapy
CN116514992B (zh) * 2022-11-07 2024-05-24 武汉波睿达生物科技有限公司 一种信号肽序列优化的靶向cd19的嵌合抗原受体及其应用
AU2024230609A1 (en) 2023-02-28 2025-09-04 Juno Therapeutics, Inc. Cell therapy for treating systemic autoimmune diseases
CN120641113A (zh) 2023-03-31 2025-09-12 西比曼生物科技集团 靶向cd20和bcma的双特异性嵌合抗原受体
CN119954967A (zh) * 2023-05-19 2025-05-09 优恺泽生物医药(上海)有限公司 免疫效应细胞及其应用
WO2025021113A1 (zh) * 2023-07-25 2025-01-30 上海药明巨诺生物医药研发有限公司 用于治疗与cd20相关的疾病的融合蛋白
WO2025030693A1 (zh) * 2023-08-08 2025-02-13 星尘生物科技(上海)有限公司 双特异性嵌合抗原受体及其应用
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US6074841A (en) 1996-08-19 2000-06-13 Millennium Biotherapeutics, Inc. Don-1 gene and polypeptides and uses therefor
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
ATE338124T1 (de) 2000-11-07 2006-09-15 Hope City Cd19-spezifische umgezielte immunzellen
US8287864B2 (en) 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
KR100932340B1 (ko) 2002-10-17 2009-12-16 젠맵 에이/에스 Cd20에 대한 인간 모노클로날 항체
JP4733635B2 (ja) 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗cd19抗体
KR20120125634A (ko) 2003-10-16 2012-11-16 마이크로메트 에이지 다중특이적 탈면역화된 cd3-바인더
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
CA2656620C (en) 2006-07-04 2018-03-13 Genmab A/S Cd20 binding molecules for the treatment of copd
EP2856876B1 (en) 2007-03-30 2018-01-31 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
EP2167130A2 (en) 2007-07-06 2010-03-31 Trubion Pharmaceuticals, Inc. Binding peptides having a c-terminally disposed specific binding domain
AU2008282152B2 (en) 2007-07-31 2013-12-19 Regeneron Pharmaceuticals, Inc. Human antibodies to human CD20 and method of using thereof
SI2211904T1 (sl) 2007-10-19 2016-12-30 Seattle Genetics, Inc. CD19 vezavna sredstva in njihove uporabe
WO2009052830A1 (en) 2007-10-22 2009-04-30 Genmab A/S Novel antibody therapies
CN101544694A (zh) 2008-03-28 2009-09-30 上海中信国健药业有限公司 抗cd20四价抗体、其制备方法和应用
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP3594245A1 (en) 2012-02-13 2020-01-15 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
DK3473707T3 (da) 2012-05-25 2025-03-17 Cellectis Fremgangsmåder til engineering af allogen og immunsuppressiv resistent t-celle til immunoterapi
EP2872170A4 (en) 2012-07-13 2016-06-22 Zymeworks Inc ASYMMETRIC BISPECIFIC HETERODIMERS WITH ANTI-CD3 CONSTRUCTS
IL293944A (en) 2012-08-20 2022-08-01 Hutchinson Fred Cancer Res Method and preparations for cellular immunotherapy
DK2956175T3 (da) 2013-02-15 2017-11-27 Univ California Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
US9499855B2 (en) 2013-03-14 2016-11-22 Elwha Llc Compositions, methods, and computer systems related to making and administering modified T cells
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
JP2015092865A (ja) 2013-11-13 2015-05-18 国立大学法人名古屋大学 ヒト化抗cd20キメラ抗原レセプター
MX386422B (es) * 2013-12-20 2025-03-18 Fred Hutchinson Cancer Center Moléculas efectoras químericas etiquetadas y receptores de las mismas.
ES2767423T3 (es) 2014-01-13 2020-06-17 Hope City Receptores de antígenos quiméricos (CARS) con mutaciones en la región del espaciador Fc y métodos para su uso
GB201407852D0 (en) * 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
EP3149044B1 (en) 2014-06-02 2020-10-21 The U.S.A. as represented by the Secretary, Department of Health and Human Services Chimeric antigen receptors targeting cd-19
SG10201913765YA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
TWI751102B (zh) * 2014-08-28 2022-01-01 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
MX392487B (es) 2014-10-20 2025-03-21 Juno Therapeutics Inc Métodos y composiciones para dosificación en terapia celular adoptiva.
KR102804498B1 (ko) 2014-12-03 2025-05-08 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 치료를 위한 방법 및 조성물
SI3240805T1 (sl) * 2014-12-15 2025-04-30 The Regents Of The University Of California Bispecifični or-gate himerni antigenski receptor, odziv na cd19 in cd20
WO2016097231A2 (en) 2014-12-17 2016-06-23 Cellectis INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN
WO2016110576A1 (en) 2015-01-08 2016-07-14 Genmab A/S Bispecific antibodies against cd3 and cd20
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
KR20170110601A (ko) 2015-02-05 2017-10-11 몰레큘러 템플레이츠, 인코퍼레이션. 시가 독소 a 서브유닛 작동체 영역을 포함하는 다가 cd20 결합 분자 및 이들의 강화된 조성물
US11248058B2 (en) 2015-02-19 2022-02-15 University Of Florida Research Foundation, Inc. Chimeric antigen receptors and uses thereof
MA41613A (fr) 2015-02-23 2018-01-02 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
GB201503742D0 (en) * 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
HRP20220893T1 (hr) 2015-04-08 2022-10-14 Novartis Ag Cd20 terapije, cd22 terapije, i kombinirane terapije sa stanicom koja eksprimira cd19 kimerni antigenski receptor
GB201506223D0 (en) 2015-04-13 2015-05-27 Ucl Business Plc Chimeric protein
WO2016168773A2 (en) * 2015-04-15 2016-10-20 The California Institute For Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
WO2016176651A2 (en) * 2015-04-29 2016-11-03 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
WO2016179319A1 (en) 2015-05-04 2016-11-10 Cellerant Therapeutics, Inc. Chimeric antigen receptors with ctla4 signal transduction domains
CN108603170A (zh) 2015-06-12 2018-09-28 莱蒂恩技术公司 用工程改造的t细胞治疗癌症的方法
US10493139B2 (en) * 2015-07-24 2019-12-03 Innovative Cellular Therapeutics CO., LTD. Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
SG10201912734PA (en) 2015-08-05 2020-02-27 Yoo Young Pharm Co Ltd Chimeric antigen receptor, and t cells in which chimeric antigen receptor is expressed
US11458167B2 (en) 2015-08-07 2022-10-04 Seattle Children's Hospital Bispecific CAR T-cells for solid tumor targeting
CN105384825B (zh) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
CN108135932A (zh) 2015-08-28 2018-06-08 宾夕法尼亚大学董事会 表达嵌合细胞内信号传导分子的细胞的方法和组合物
CN108602872A (zh) 2015-10-30 2018-09-28 艾丽塔生物治疗剂公司 用于治疗癌症的组合物和方法
MA44314A (fr) * 2015-11-05 2018-09-12 Juno Therapeutics Inc Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
AU2017225733A1 (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
MX2018010415A (es) 2016-03-18 2018-11-29 Hutchinson Fred Cancer Res Composiciones y metodos para inmunoterapia de grupo de diferenciacion 20 (cd20).
KR20230148844A (ko) * 2016-03-29 2023-10-25 유니버시티 오브 써던 캘리포니아 암을 표적하는 키메라 항원 수용체
CA3018253A1 (en) * 2016-03-31 2017-10-05 University Of Southern California A highly sensitive and specific luciferase based reporter assay for antigen detection
US10603380B2 (en) 2016-04-01 2020-03-31 Kite Pharma, Inc. Chimeric antigen and T cell receptors and methods of use
CN107868791B (zh) * 2016-09-26 2021-11-23 阿思科力(苏州)生物科技有限公司 一种加强型Slit2 CAR-T和CAR-NK细胞制备方法和应用
AU2017341047B2 (en) * 2016-10-07 2024-10-10 Novartis Ag Chimeric antigen receptors for the treatment of cancer
CN107936120B (zh) * 2016-10-13 2021-03-09 上海赛比曼生物科技有限公司 Cd19靶向性的嵌合抗原受体及其制法和应用
EP3336107A1 (en) * 2016-12-15 2018-06-20 Miltenyi Biotec GmbH Immune cells expressing an antigen binding receptor and a chimeric costimulatory receptor
CN108250301A (zh) 2016-12-29 2018-07-06 天津天锐生物科技有限公司 一种多靶点嵌合抗原受体
CN108276493B (zh) 2016-12-30 2023-11-14 南京传奇生物科技有限公司 一种嵌合抗原受体及其应用
CN108395482B (zh) * 2017-02-08 2021-02-05 西比曼生物科技(香港)有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
AU2018225153A1 (en) * 2017-02-22 2019-09-19 Aleta Biotherapeutics Inc. Compositions and methods for tumor transduction
KR20190133017A (ko) 2017-03-27 2019-11-29 에프. 호프만-라 로슈 아게 개선된 항원 결합 수용체 구성
JOP20180042A1 (ar) 2017-04-24 2019-01-30 Kite Pharma Inc نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
US11434290B2 (en) 2017-06-08 2022-09-06 H. Lee Moffitt Cancer Center And Research Institute, Inc. Chimeric antigen receptors with enhanced NFκB signaling
WO2019028051A1 (en) 2017-07-31 2019-02-07 Lentigen Technology, Inc. COMPOSITIONS AND METHODS FOR TREATING CANCER BY ANTI-CD19 / CD20 IMMUNOTHERAPY
CN109423495A (zh) 2017-08-24 2019-03-05 上海恒润达生生物科技有限公司 一种双靶向嵌合抗原受体及其用途
US10501539B2 (en) 2017-09-15 2019-12-10 Lentigen Technology Inc. Compositions and methods for treating cancer with anti-CD19 immunotherapy
US11905528B2 (en) 2017-10-12 2024-02-20 Icell Gene Therapeutics Inc. Compound chimeric antigen receptor (cCAR) targeting multiple antigens, compositions and methods of use thereof
TW201922256A (zh) * 2017-10-27 2019-06-16 中國大陸商浙江導明醫藥科技有限公司 治療淋巴樣惡性疾病之方法
EP3710471A1 (en) 2017-11-16 2020-09-23 Kite Pharma, Inc. Modified chimeric antigen receptors and methods of use
US20220218745A1 (en) 2017-12-22 2022-07-14 2Seventy Bio, Inc. Multivalent chimeric antigen receptor
CN108315305B (zh) 2017-12-26 2020-11-06 沣潮医药科技(上海)有限公司 携带嵌合抗原受体的免疫细胞外泌体的制备方法及其应用
CN109971725B (zh) 2017-12-28 2024-02-02 上海细胞治疗研究院 抗体修饰的嵌合抗原受体修饰t细胞及其用途
CN108285486A (zh) 2018-01-15 2018-07-17 浙江阿思科力生物科技有限公司 以cd20为靶点的特异性抗体、car-nk细胞及其制备和应用
CN108017717B (zh) 2018-01-24 2019-08-16 首都医科大学宣武医院 一种用于体外高效定向扩增的嵌合抗原受体及其应用
US20230183313A1 (en) 2018-02-11 2023-06-15 Jiangsu Hengrui Medicine Co., Ltd. Isolated chimeric antigen receptor, modified t cell comprising same and use thereof
CN108715616A (zh) * 2018-04-27 2018-10-30 上海恒润达生生物科技有限公司 靶向人源化间皮素的嵌合抗原受体方法和用途
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
KR20210033941A (ko) 2018-04-28 2021-03-29 이뮤노테크 바이오팜 씨오., 엘티디. 개선된 t-세포 요법
CN110526983B (zh) 2018-05-24 2022-02-11 北京马力喏生物科技有限公司 改良型抗cd19 car-t细胞
WO2019232444A1 (en) 2018-05-31 2019-12-05 Washington University Chimeric antigen receptor t cells (car-t) for the treatment of cancer
CN110606893B (zh) 2018-06-15 2022-11-15 北昊干细胞与再生医学研究院有限公司 一种靶向cd19和cd20双抗原的嵌合性抗原受体t细胞治疗肿瘤的方法
US12036242B2 (en) 2018-07-05 2024-07-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. CAR T cells that target B-cell antigens
WO2020033273A1 (en) 2018-08-04 2020-02-13 AbCyte Therapeutics Inc. Multi-function and multi-targeting car system and methods for use thereof
JP2022501067A (ja) 2018-09-26 2022-01-06 上海恒潤達生生物科技有限公司Hrain Biotechnology Co., Ltd. Bcma及びcd19を標的とするキメラ抗原受容体、並びにその使用
SG11202103235PA (en) 2018-10-01 2021-04-29 Adicet Bio Inc COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON- ENGINEERED γδ-Τ CELLS FOR TREATMENT OF HEMATOLOGICAL TUMORS
CN109536455B (zh) 2018-12-11 2020-02-21 武汉波睿达生物科技有限公司 一种car-nk细胞及其制备方法和应用
CN113412117B (zh) * 2018-12-12 2025-03-04 凯德药业股份有限公司 嵌合抗原和t细胞受体及使用的方法
CN109575143B (zh) * 2018-12-29 2022-06-17 博生吉医药科技(苏州)有限公司 双特异性cd20-cd19-car及其应用
CN113330038A (zh) 2019-01-22 2021-08-31 亘喜生物科技(上海)有限公司 Cd20组合靶向的工程化免疫细胞
JP7395200B2 (ja) 2019-03-25 2023-12-11 イミュンワーク インク. 金属結合モチーフを有する複合ポリペプチド及びそれを備える分子構築物
CN112390891B (zh) 2019-08-14 2022-06-03 苏州方德门达新药开发有限公司 嵌合抗原受体及其构建方法和应用
CN110845623B (zh) * 2019-10-11 2021-07-09 厦门大学 一种egfr特异性嵌合抗原受体及其应用
US20230212255A1 (en) 2020-03-17 2023-07-06 Cellular Biomedicine Group Inc. Combined chimeric antigen receptor targeting cd19 and cd20 and applications thereof
US20230104705A1 (en) 2020-03-17 2023-04-06 Cellular Biomedicine Group Inc. Combined chimeric antigen receptor targeting cd19 and cd20 and application thereof
CN113402612A (zh) 2020-03-17 2021-09-17 西比曼生物科技(香港)有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
CN112608387B (zh) 2020-12-21 2023-05-05 汤朝阳 Cd19和cd20双靶点嵌合抗原受体及其应用
US20240115605A1 (en) 2021-01-27 2024-04-11 Cellular Biomedicine Group, Inc. Chimeric antigen receptors targeting cd20

Similar Documents

Publication Publication Date Title
JP2025066770A5 (enExample)
CN308411902S (enExample)
CN308403415S (enExample)
CN308407664S (enExample)
CN308407648S (enExample)
CN308407583S (enExample)
CN308407546S (enExample)
CN308407236S (enExample)
CN308407147S (enExample)
CN308408898S (enExample)
CN308405651S (enExample)
CN308405208S (enExample)
CN308404848S (enExample)
CN309645795S (enExample)
CN309312257S (enExample)
CN309694558S (enExample)
CN309685878S (enExample)
CN309675061S (enExample)
CN309503272S (enExample)
CN309477758S (enExample)
CN309459444S (enExample)
CN308404841S (enExample)
CN308407764S (enExample)
CN309389811S (enExample)
CN309312164S (enExample)